Ductal carcinoma in situ (DCIS) represents a clinical crossroads in breast surgery—balancing the risks of over-treatment with the need to prevent invasive cancer. With new data from active monitoring trials, the pressure is on for surgeons to personalize care. Tune in to this essential episode to stay ahead of the curve on DCIS management and to hear expert insights from two leading breast surgical oncologists.



Hosts:

- Rashmi Kumar, MD, PhD

Resident, University of Michigan General Surgery Residency Program

Twitter/X: @RashmiJKumar

- Melissa Pilewskie, MD

Attending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine

Twitter/X: @MPilewskie

-  Stephanie Downs-Canner, MD

Attending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program

Twitter/X: @SDownsCanner



Learning Objectives:

- Define DCIS and explain its significance as a precursor to invasive breast cancer.

- Discuss challenges in diagnosing and risk-stratifying DCIS.

- Review current standards for surgical and adjuvant management of DCIS.

- Understand the implications of new research, including the COMET trial, for low-risk DCIS.

- Evaluate patient-centered strategies for managing DCIS and preventing over-treatment.



References:

- Worni M, Akushevich I, Greenup R, et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst. 2015;107(12):djv263. PubMed

- Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015 Jan;51(16):2296-303. PubMed

- Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a non-surgical management strategy for low-grade DCIS: The LORD study. Eur J Cancer. 2015;51(12):1497–1510. PubMed

- Toss MS, et al. Ductal carcinoma in situ (DCIS): current management and future directions. Cancer Treat Rev. 2020;90:10 2091. PubMed

- Comparative Effectiveness of Surgery versus Active Monitoring for Low-Risk DCIS (COMET) Trial Results. Early COMET Results: King TA, et al. Surgical excision versus active monitoring for low-risk ductal carcinoma in situ (DCIS): 2-year results of the COMET randomized trial. J Clin Oncol. 2024; e2400110. PubMed



Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen

Behind the Knife Premium:

General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review

Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas

Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship

Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation

Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review

Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review

Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review

Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review

Download our App:

Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049

Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US